NLS Pharmaceutics CEO Issues Letter to Shareholders

Stock Information for NLS Pharmaceutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
Notice of Deficiency with Nasdaq Continued Listing Requirements
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.